An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis; Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Circassia
- 29 Jun 2017 This trial has been discontinued in Germany.
- 18 Jun 2017 This trial has been discontinued in Czech Republic.
- 22 Mar 2016 Planned primary completion date changed from 1 May 2018 to 1 May 2019 as reported by ClinicalTrials.gov.